BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today ...
TipRanks on MSN
FDA clears Abpro’s lead HER2 cancer drug for phase 1
The latest update is out from Abpro Holdings ( (ABP) ).
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, ...
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents ...
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (ABP) (“Abpro” or the “Company”) ...
WOBURN, Mass. & NEW YORK--(BUSINESS WIRE)--Abpro Corporation (“Abpro”), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback